Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

Investigational New Drugs - Tập 36 Số 1 - Trang 121-135 - 2018
Joanna C. Masters1, Dana Nickens2, Dawei Xuan3, Ronald Shazer4, Michael Amantea5
1Clinical Pharmacology, Oncology, Global Product Development, Pfizer Inc, San Diego, USA
2Global Pharmacometrics, Global Product Development, Pfizer Inc., 10555 Science Center Drive, San Diego, CA, 92121, USA.
3Clinical Pharmacology, Early Oncology Development & Clinical Research, Worldwide Research and Development, Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 92121, USA.
4Inspyr Therapeutics, Inc., 31200 Via Colinas, Suite 200, Westlake Village, CA, 91362, USA
5Global Pharmacometrics, Global Product Development, Pfizer Inc., San Diego, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Beck A, Goetsch L, Dumontet C, Corvaia N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16(5):315–337. https://doi.org/10.1038/nrd.2016.268

Bouchard H, Viskov C, Garcia-Echeverria C (2014) Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett 24(23):5357–5363. https://doi.org/10.1016/j.bmcl.2014.10.021

Chari RV, Miller ML, Widdison WC (2014) Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 53(15):3796–3827. https://doi.org/10.1002/anie.201307628

Agresti AC, Brent A (1998) Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 52(2):119–126